Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung disease
Biotech
AIRNA preps for clinical test with $155M series B
AIRNA's tech makes targeted adenosine-to-inosine edits in RNA, which the firm hopes can provide a functional cure for alpha-1 antitrypsin deficiency.
Darren Incorvaia
Apr 1, 2025 7:00am
Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
Feb 10, 2025 10:42am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
After phase 2 data, Insilico plots pivotal lung disease trial
Nov 12, 2024 1:34pm
The Column Group biotech taps Surrozen to target lung fibrosis
Nov 4, 2024 11:14am
Amgen disappears lung disease program after phase 2 fail
Oct 30, 2024 5:59pm
